Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL) Meeting Abstract
| Authors: | Andreadis, C.; Fenske, T. S.; Hill, B. T.; Stiff, P. J.; Grinblatt, D. L.; Hsi, E. D.; Kelley, T.; Richards, K. L.; Kostakoglu, L.; Schoder, H.; Jung, S. H.; Pitcher, B.; Pike, K.; Plona, T.; Baugher, R.; Mellot, S.; Bartlett, N. L.; Leonard, J.; Shea, T. C.; Devine, S. M. |
| Abstract Title: | Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 408s |
| Language: | English |
| ACCESSION: | WOS:000411932200021 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.TPS7566 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS7566 -- Source: Wos |
